Disease Control Achieved Using Atezolizumab + Bevacizumab in | Figure 1

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trial demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.

Read the full case here:

Extrahepatic Metastasis of Hepatocellular Carcinoma (HCC)

Cases of Hepatocellular Carcinoma

Patient with #Hepatocellular-carcinoma presenting with progressive SOB.

Axial T2-weighted MRI show a fibrolamellar hepatocellular carcinoma in the mid liver.

Portal vein thrombosis in the setting of hepatocellular carcinoma; newly diagnosed HCV

Trending Cases

A 52-year-old man presented with a 20-minute history of chest pain radiating to the left shoulder and neck, associated with dyspnea and diaphoresis.

A 28-year-old woman presented with a 3-day history of intense pruritus over the lower back.

A 4-month-old male infant presented with skin lesions localized to the chin for the past 3 days.

Patient in late teens presenting after a collapse, no previous cardiac history.